ABSI Stock Analysis: Absci | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.900m USD | 12M Return: 153.4% | US00091E1091 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 40.5M
Qual. Beats: 0
Rev. Trend: -88.6%
Qual. Beats: -4
Warnings
Tailwinds
Seasonality 5.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Absci Corporation (NASDAQ: ABSI) is a clinical-stage biopharmaceutical company based in Vancouver, Washington, that develops antibody therapeutics. Its pipeline includes ABS-101 in Phase 1 trials for inflammatory bowel disease, ABS-201 in Phase 1/2a trials for androgenic alopecia, and earlier-stage programs ABS-301 and ABS-501 targeting immuno-oncology and oncology, respectively. Founded in 2011 and listed on Nasdaq in 2021, the company maintains research and development collaborations with partners including PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices.
As a clinical-stage biotech, Absci does not yet have approved products or commercial revenue, so its operations depend on capital markets, partnership income, and the advancement of its drug pipeline. Its collaborations with major technology firms such as Oracle and AMD suggest the use of computational and AI-driven approaches in its antibody discovery and development process, a growing trend in the biotechnology sector.
- ABS-101 Phase 1 IBD data readout could revalue pipeline
- AI drug discovery partnerships with AMD and Oracle drive collaboration revenue
- Cash burn accelerates as clinical pipeline advances toward key milestones
| Net Income: -121.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.41 > 0.02 and ΔFCF/TA -3.97 > 1.0 |
| NWC/Revenue: 12.1k% < 20% (prev 2.56k%; Δ 9.52k% < -1%) |
| CFO/TA -0.40 > 3% & CFO -108.1m > Net Income -121.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (157.5m) vs 12m ago 23.42% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.65% > 50% (prev 1.97%; Δ -1.32% > 0%) |
| Interest Coverage Ratio: -1.29k > 6 (EBIT TTM -121.0m / Interest Expense TTM 94.0k) |
| A: 0.70 (Total Current Assets 208.3m - Total Current Liabilities 19.6m) / Total Assets 268.9m |
| B: -2.56 (Retained Earnings -687.6m / Total Assets 268.9m) |
| C: -0.51 (EBIT TTM -121.0m / Avg Total Assets 239.4m) |
| D: 10.80 (Book Value of Equity 246.1m / Total Liabilities 22.8m) |
| Altman-Z'' = 4.21 = AA |
As of October 11, 2026, the stock is trading at USD 10.16 with a total of 4,240,773 shares traded. Over the past week, the price has changed by -8.22%, over one month by +17.46%, over three months by -11.42% and over the past year by +153.37%.
Current recommended Stop Loss: 8.90 (which is 12.4% or 1.5 ATR below the current price).
Absci has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy ABSI.
- StrongBuy: 8
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.4 | 41.7% |
P/S = 1217.0193
P/B = 6.7947
Revenue TTM = 1.56m USD
EBIT TTM = -121.0m USD
EBITDA TTM = -109.9m USD
Long Term Debt = 1.64m USD (estimated: total debt 3.68m - short term 2.04m)
Short Term Debt = 2.04m USD (from shortTermDebt, last quarter)
Debt = 3.68m USD (from shortLongTermDebtTotal, last quarter) (leases 3.68m already included)
Net Debt = -197.5m USD (calculated: Debt 3.68m - CCE 201.1m)
Enterprise Value = 1.70b USD (1.90b + Debt 3.68m - CCE 201.1m)
Interest Coverage Ratio = -1.29k (Ebit TTM -121.0m / Interest Expense TTM 94.0k)
EV/FCF = -15.62x (Enterprise Value 1.70b / FCF TTM -109.0m)
FCF Yield = -6.40% (FCF TTM -109.0m / Enterprise Value 1.70b)
FCF Margin = -6.98k% (FCF TTM -109.0m / Revenue TTM 1.56m)
Net Margin = -7.76k% (Net Income TTM -121.1m / Revenue TTM 1.56m)
Gross Margin = unknown ((Revenue TTM 1.56m - Cost of Revenue TTM 11.7m) / Revenue TTM)
Tobins Q-Ratio = 6.33 (Enterprise Value 1.70b / Total Assets 268.9m)
Interest Expense / Debt = 2.56% (Interest Expense 94.0k / Debt 3.68m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -95.6m (EBIT -121.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.63 (Total Current Assets 208.3m / Total Current Liabilities 19.6m)
Debt / Equity = 0.01 (Debt 3.68m / totalStockholderEquity, last quarter 246.1m)
Debt / EBITDA = 1.80 (negative EBITDA) (Net Debt -197.5m / EBITDA -109.9m)
Debt / FCF = 1.81 (negative FCF - burning cash) (Net Debt -197.5m / FCF TTM -109.0m)
Total Stockholder Equity = 204.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -50.57% (Net Income -121.1m / Total Assets 268.9m)
RoE = -59.21% (Net Income TTM -121.1m / Total Stockholder Equity 204.5m)
RoCE = -58.71% (EBIT -121.0m / Capital Employed (Equity 204.5m + L.T.Debt 1.64m))
RoIC = -38.05% (negative operating profit) (NOPAT -95.6m / Invested Capital 251.3m)
WACC = 14.90% (E(1.90b)/V(1.90b) * Re(14.92%) + D(3.68m)/V(1.90b) * Rd(2.56%) * (1-Tc(0.21)))
Discount Rate = 14.92% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 98.10 | Cagr: 22.69%
[DCF] Fair Price = unknown (Cash Flow -109.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.37 | # QB: 0
Revenue Correlation: -88.56 | Revenue CAGR: -35.96% | SUE: -1.08 | # QB: -4
EPS current Quarter (2026-09-30): EPS=-0.20 | Chg30d=-1.51% | Revisions=-10% | Analysts=7
EPS current Year (2026-12-31): EPS=-0.81 | Chg30d=-3.56% | Revisions=-36% | GrowthEPS=+8.4% | GrowthRev=+39.0%
EPS next Year (2027-12-31): EPS=-0.68 | Chg30d=-8.47% | Revisions=-55% | GrowthEPS=+16.2% | GrowthRev=+310.9%
[Analyst] Revisions Ratio: -42% (up=6, down=17)